SG10201510341XA - Antigen-binding molecule inducing immune response to target antigen - Google Patents

Antigen-binding molecule inducing immune response to target antigen

Info

Publication number
SG10201510341XA
SG10201510341XA SG10201510341XA SG10201510341XA SG10201510341XA SG 10201510341X A SG10201510341X A SG 10201510341XA SG 10201510341X A SG10201510341X A SG 10201510341XA SG 10201510341X A SG10201510341X A SG 10201510341XA SG 10201510341X A SG10201510341X A SG 10201510341XA
Authority
SG
Singapore
Prior art keywords
antigen
immune response
binding molecule
inducing immune
molecule inducing
Prior art date
Application number
SG10201510341XA
Other languages
English (en)
Inventor
Tomoyuki Igawa
Atsuhiko Maeda
Kenta Haraya
Tatsuhiko Tachibana
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201510341XA publication Critical patent/SG10201510341XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201510341XA 2011-09-30 2012-09-28 Antigen-binding molecule inducing immune response to target antigen SG10201510341XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011216958 2011-09-30

Publications (1)

Publication Number Publication Date
SG10201510341XA true SG10201510341XA (en) 2016-01-28

Family

ID=47995754

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201510341XA SG10201510341XA (en) 2011-09-30 2012-09-28 Antigen-binding molecule inducing immune response to target antigen
SG11201401100UA SG11201401100UA (en) 2011-09-30 2012-09-28 Antigen-binding molecule inducing immune response to target antigen

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201401100UA SG11201401100UA (en) 2011-09-30 2012-09-28 Antigen-binding molecule inducing immune response to target antigen

Country Status (14)

Country Link
US (2) US10556949B2 (fr)
EP (1) EP2752200B1 (fr)
JP (3) JP6352634B2 (fr)
KR (3) KR102239138B1 (fr)
CN (4) CN104093424A (fr)
AU (1) AU2012317395B2 (fr)
BR (1) BR112014007484A2 (fr)
CA (1) CA2850322C (fr)
HK (1) HK1198813A1 (fr)
MX (2) MX366968B (fr)
RU (1) RU2722829C9 (fr)
SG (2) SG10201510341XA (fr)
TW (2) TW201945034A (fr)
WO (1) WO2013047729A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP2679681B2 (fr) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Anticorps Fc spécifique de FcgammaRIIb
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
DK2818478T3 (en) 2011-10-28 2017-05-22 Regeneron Pharma HUMANIZED IL-6 AND IL-6 RECEPTOR
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
ES2795419T3 (es) * 2012-02-24 2020-11-23 Chugai Pharmaceutical Co Ltd Molécula de unión al antígeno que promueve la desaparición del antígeno vía Fc RIIB
JPWO2013180200A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
JP6282591B2 (ja) 2012-09-13 2018-02-21 中外製薬株式会社 遺伝子ノックイン非ヒト動物
EP2940135B9 (fr) 2012-12-27 2021-09-08 Chugai Seiyaku Kabushiki Kaisha Polypeptide hétérodimérisé
GB201302878D0 (en) * 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
WO2017222593A1 (fr) * 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Récepteurs d'antigènes chimériques (car), compositions et procédés associés
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
WO2018052556A1 (fr) 2016-08-02 2018-03-22 Visterra, Inc. Polypeptides synthétiques et leurs utilisations
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
US10669344B2 (en) * 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
AU2018255938A1 (en) 2017-04-21 2019-10-31 Staten Biotechnology B.V. Anti-ApoC3 antibodies and methods of use thereof
WO2019087115A1 (fr) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs procédés d'utilisation
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2020032230A1 (fr) * 2018-08-10 2020-02-13 中外製薬株式会社 Molécule de liaison à l'antigène anti-cd137 et utilisation associée
US20230183379A1 (en) 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
AU2020280543A1 (en) * 2019-05-23 2022-01-27 Xiamen University Anti-hepatitis B virus antibodies and use thereof
EP4086281A4 (fr) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd Récepteur star de lymphocytes t amélioré et son application
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
US20240174730A1 (en) * 2021-02-25 2024-05-30 Cidara Therapeutics, Inc. Variant fc domains and uses thereof
CN113332417A (zh) * 2021-04-27 2021-09-03 大汉生物科技(广东)有限公司 Trem-2在制备肿瘤治疗药物和/或诊断试剂中的应用
CN114921436B (zh) * 2022-03-03 2023-08-04 翌圣生物科技(上海)股份有限公司 末端脱氧核苷酸转移酶突变体、其编码基因、重组表达质粒和基因工程菌
CN114716547B (zh) * 2022-05-18 2023-11-21 珠海丽禾医疗诊断产品有限公司 一种包括抗原结合结构域的结合蛋白及其生产方法和应用
CN115028685B (zh) * 2022-06-24 2023-10-20 张金强 一种阳离子双环抗菌肽及其应用
CN115353566B (zh) * 2022-09-14 2023-05-09 江苏睿源生物技术有限公司 用于检测白细胞介素1-β的抗体组合及其应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
WO1994025585A1 (fr) 1993-04-26 1994-11-10 Genpharm International, Inc. Animaux transgeniques capables de produire des anticorps heterologues
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (fr) 1991-12-17 2008-04-08 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
EP0652950B1 (fr) 1992-07-24 2007-12-19 Amgen Fremont Inc. Production d'anticorps xenogeniques
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
WO1995015388A1 (fr) 1993-12-03 1995-06-08 Medical Research Council Proteines et peptides de liaison recombines
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
CA2704600C (fr) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. Methode de production d'anticorps avec activite adcc accrue
EP2149604A1 (fr) 2000-09-08 2010-02-03 Universität Zürich Collections de protéines de répétition comportant des modules de répétition
EP1331266B1 (fr) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cellules produisant des compositions d'anticorps
CA2418835A1 (fr) 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
WO2002079255A1 (fr) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation Anticorps recombinants co-exprimes avec gntiii
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP2208784B1 (fr) 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de prolifération de cellules contenant un anticorps anti-glypican 3
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
ES2624547T3 (es) * 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anticuerpos anti il 6, composiciones, métodos y usos
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003104453A1 (fr) 2002-06-05 2003-12-18 中外製薬株式会社 Procede de construction d'anticorps
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
AU2003236537A1 (en) * 2002-06-21 2004-01-06 Thomson Licensing S.A. Linearly expandable broadcast router apparatus
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
CN1918178B (zh) 2004-01-12 2012-08-22 应用分子进化公司 Fc区变体
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
EP2314317A3 (fr) 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypican 3
EP2940043A1 (fr) 2004-07-15 2015-11-04 Xencor, Inc. Variantes optimisées de fc
EP1776384B1 (fr) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Regions fc de variants
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
CA2587766A1 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
CN102746404B (zh) * 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
WO2006106905A1 (fr) * 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
WO2006116260A2 (fr) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
CA2605781A1 (fr) * 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
WO2006130384A2 (fr) 2005-05-27 2006-12-07 The Glad Products Company Dispositif et procede destines a evacuer un sac de stockage
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
ES2526811T3 (es) 2005-08-10 2015-01-15 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
BRPI0615397B1 (pt) * 2005-08-26 2023-10-03 Roche Glycart Ag Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
EP1931709B1 (fr) 2005-10-03 2016-12-07 Xencor, Inc. Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
US20120189640A1 (en) 2006-08-02 2012-07-26 The Uab Research Foundation Methods and Compositions Related to Soluble Monoclonal Variable Lymphocyte Receptors of Defined Antigen Specificity
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
US7994290B2 (en) * 2007-01-24 2011-08-09 Kyowa Hakko Kirin Co., Ltd Effector function enhanced recombinant antibody composition
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
PL2235059T3 (pl) 2007-12-26 2015-08-31 Xencor Inc Warianty FC o zmodyfikowanym wiązaniu do FCRN
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
JP2011519279A (ja) * 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
SG195558A1 (en) * 2008-10-14 2013-12-30 Genentech Inc Immunoglobulin variants and uses thereof
WO2010058860A1 (fr) * 2008-11-18 2010-05-27 株式会社シノテスト Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
SG2014007637A (en) * 2009-01-29 2014-03-28 Medimmune Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
WO2011008517A2 (fr) * 2009-06-30 2011-01-20 Research Development Foundation Polypeptides fc d'immunoglobuline
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
EP2679681B2 (fr) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Anticorps Fc spécifique de FcgammaRIIb
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013046722A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Bibliothèque de molécules de liaison dépendant de la concentration ionique
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
KR102143331B1 (ko) 2011-09-30 2020-08-11 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
JPWO2013180200A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
EP3050896B1 (fr) * 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Procédé de production d'un hétéromultimère polypeptidique
AU2015283270B9 (en) 2014-06-30 2021-04-01 Merck Patent Gmbh Anti-TNFa antibodies with pH-dependent antigen binding
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
US11142587B2 (en) * 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer

Also Published As

Publication number Publication date
JP2018150378A (ja) 2018-09-27
TWI681970B (zh) 2020-01-11
BR112014007484A2 (pt) 2017-04-04
EP2752200A4 (fr) 2015-04-22
MX366968B (es) 2019-08-01
US20140255398A1 (en) 2014-09-11
RU2722829C2 (ru) 2020-06-05
CN110627902A (zh) 2019-12-31
SG11201401100UA (en) 2014-07-30
AU2012317395A1 (en) 2014-05-01
EP2752200B1 (fr) 2023-11-01
JP7029355B2 (ja) 2022-03-03
TW201326210A (zh) 2013-07-01
JP6352634B2 (ja) 2018-07-04
JPWO2013047729A1 (ja) 2015-03-26
CN110655578A (zh) 2020-01-07
EP2752200A1 (fr) 2014-07-09
TW201945034A (zh) 2019-12-01
KR20140076594A (ko) 2014-06-20
KR20220025928A (ko) 2022-03-03
US10556949B2 (en) 2020-02-11
KR102492584B1 (ko) 2023-01-27
EP2752200C0 (fr) 2023-11-01
KR102366029B1 (ko) 2022-02-23
CA2850322A1 (fr) 2013-04-04
CN104093424A (zh) 2014-10-08
RU2014117504A (ru) 2015-11-10
US20200115447A1 (en) 2020-04-16
MX2014003832A (es) 2014-08-27
KR102239138B1 (ko) 2021-04-12
CN110680920A (zh) 2020-01-14
HK1198813A1 (en) 2015-06-12
JP2022000472A (ja) 2022-01-04
KR20210035312A (ko) 2021-03-31
RU2722829C9 (ru) 2020-09-22
WO2013047729A1 (fr) 2013-04-04
MX2019006188A (es) 2019-10-02
CA2850322C (fr) 2023-10-10
AU2012317395B2 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
HK1198813A1 (en) Antigen-binding molecule inducing immune response to target antigen
IL276234B (en) Antibody compositions
HRP20181690T1 (hr) Varijante protutijela fc
HK1198578A1 (en) Antigen-binding molecule for promoting elimination of antigens
IL229254A0 (en) Therapeutic antibodies
CO7020871A2 (es) Anticuerpos anti-il-36r
ZA201400768B (en) Interleukin-31 monoclonal antibody
IL228001A0 (en) Antibodies to 70cd
DK3275892T3 (da) Præfusions-rsv-f-antigener
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
IL227796A0 (en) Methods for enhancing immunogen-specific immune responses by carrier vaccines
CO6841994A2 (es) Anticuerpos
EP2714074A4 (fr) Anticorps anti-emr1
ZA201308992B (en) Therapeutic antibodies